Kornimate/medical-research-clean huggingface dataset:
longitudinal assessment of biomarkers after oesophagogastric cancer surgery

Conditions: Oesophageal Adenocarcinoma; Gastric Adenocarcinoma

Summary: oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in england and wales with 16,000 new cases diagnosed every year. survival rates are poor with only 15% surviving beyond 5 years. there is also increasing research to understand the cancer biology and factors allowing cancers to progress. it is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. the bioresource 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. this longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis.


Eligibility criteria:
inclusion criteria: * aged 18-90 years at the time of initial recruitment * gastric/oesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into bioresource 1 exclusion criteria: * oesophageal squamous cell carcinoma * previous oesophageal and gastric resection * history of another cancer within five years. if a new other cancer type is diagnosed within the sampling time frame, no further samples will be taken. * participants with co-morbidities preventing breath collection * unable or unwilling to provide informed written consent * pregnant women
study on the application of saliva ebv-dna detection in ebv infection related diseases

Conditions: EBV Infection

Summary: this study is a single-center, prospective, observational clinical study to evaluate the application of saliva ebv-dna detection in ebv infection related diseases


Eligibility criteria:
inclusion criteria: 1. according to the hlh-04 diagnostic criteria, it meets the hlh diagnostic criteria. ebv infection occurs in cells with ebv-dna copy number significantly increased in peripheral blood or tissue, or where ebv coding small rna(eber) is detected in tissue or peripheral blood. or straus' 1988 diagnostic criteria for caebv. 2. informed consent exclusion criteria: 1. patients who cannot cooperate with saliva collection 2. patients who are unwilling to cooperate with the project research according to the project research plan.
complex regional pain syndrome in children: impact of bergès relaxation on the autonomic balance

Conditions: Complex Regional Pain Syndrome Type I

Summary: complex regional pain syndrome (crps) is a disease provoking chronic pain in the limbs, following a trauma. patient care is complicated by the variable clinical picture and response to treatment. the stress level of the organization, for chronic pain impacts the regulation of the autonomic balance. the study of time and frequency domain analysis of heart rate variability (hrv) allows non-invasive and reproducible assessment of the autonomic balance.

the hypothesis in this study is that the sympathovagal balance could be altered in children with crps. but the impact of relaxation on pain and balance has been proven. this study aims to assess the impact of the assumption by the relaxation therapy in children suffering from crps, on sympathovagal balance. it is an experimental prospective single-center study to highlight after a standardized relaxation program, changes in the time and frequency indices variability in heart rate, parameters of pain and quality of life with the crps children 6 to 16 years.

Eligibility criteria:
inclusion criteria: * parents affiliates or entitled to a social security scheme * children from 6 to 16 years with complex regional pain syndrome (crps) type 1 * diagnosis according to the budapest criteria. exclusion criteria: * child with pathologies reaching the central nervous system or the brain stem. * children with a severe pathology of cardio-respiratory or heart being referred to treatment. * children requiring emergency surgery or trauma or septic or inflammatory context. * children with some psychiatric diseases * children who no understand french enough

Keywords: children complex regional pain syndrome relaxation bergès relaxation pain
prospective evaluation of safety and efficacy of two forms of corneal stromal hydration

Conditions: Cataract

Summary: the study objective is to compare traditional and wong methods of wound hydration for wound sealing following cataract surgery.


Eligibility criteria:
inclusion criteria: * visually significant cataract requiring surgery exclusion criteria: * evidence of fuch's dystrophy, anterior basement membrane dystrophy, or corneal thinning or scarring * any intraoperative complications * cataract incision length \< 1 mm * pregnancy
t21,18 and 13 screening by cell free fetal dna in low risk patients

Conditions: Trisomy 21, 18 and 13 Screening

Summary: the purpose of this study is to evaluate the performance of non invasive screening in a population of pregnant women with and without in vitro fertilisation (ivf) concomitantly to regular first trimester trisomy 21 (t21) screening using maternal age, nucal fold measurement and serum screening.

all pregnant women in 9 institutions in france will be offer both regular first trimester screening for trisomy 21 (t21) and cell free dna non invasive (ni) screening test at the same time. specificity and the positive and negative predictive values of the ni test will be analysed. the population will be divided in women who did and did not get pregnant after an in vitro fertilisation (ivf) procedure.

Eligibility criteria:
inclusion criteria: * age \>18 * singleton pregnancy * having a spontaneous pregnancy or obtained by amp , * having chosen to carry out a screening of the t21 to the first or second trimester of pregnancy , * gestational age \>=10 weeks of amenorrhea * consenting to invasive prenatal diagnosis, * having health insurance, * having signed the informed consent exclusion criteria: * the patients whose fetus has an abnormality on the first trimester ultrasound including nuchal translucency \> 3.5mm , * participant to another biomedical research. * pregnancy twins including the presence of a twin vanishing

Keywords: cell free fetal dna general population screening trisomy 21 ivf
anterior bridging cage with bone substitute versus localized autobone in transforaminal lumbar interbody arthrodesis

Conditions: Stenosis; Fusion of Spine (Disease)

Summary: the purpose of this study is to evaluation for the pattern of bone bridging of patients who undergo transforaminal lumbar interbody arthrodesis, the investigators hypothesize that auto local bone mixed with β-calcium phosphate + hydroxyapatite (osteon 2, genoss) is not inferior to auto local bone only. in addition, the investigators will analyze anterior new bone bridging pattern between anterior bridging cage newly developed and grafted bone in anterior disc space.

a single center, observational, single arm study to evaluate the efficacy of auto local bone mixed with β-calcium phosphate + hydroxyapatite using interbody fusion assessment on multi-axial ct scan. its active comparator is auto local bone. anterior bridging bone between anterior grafted bone and inserted cage will be assessed by using newly developed anterior bridging cage as well as interbody bone bridging between two vertebral bodies on multi-axial reconstructed ct scan. the patients undergoes arthrodesis surgery will have two cages, one augmented with auto local bone will be located at left side of disc space and the other cage augmented with auto local bone mixed with β-calcium phosphate + hydroxyapatite at right side of disc space.

Eligibility criteria:
inclusion criteria: * patients who need lumbar interbody fusion in degenerative spine disease on l1-s1(spinal stenosis, hivd and internal derangement of disk, spine instability) * patients who have no communication problems * patients who are willing to visit the hospital for any follow-up assessment * patients who voluntarily sign on a written consent exclusion criteria: * patients who have infection * patients who have bleeding disorders * patients who have immunosuppressed disease * patients who can't sign on consent form * patients who are in pregnancy or breast feeding * patients who have severe osteoporosis * patients who can't take general surgery because of severe liver disease or decreased renal function * patients who have acute spinal injury, spinal tumor or inflammatory spinal disease

Keywords: bone bridging arthrodesis lumbar cage
study to evaluate bi-weekly dosing of gemcitabine plus nab-paclitaxel to treat metastatic pancreatic cancer

Conditions: Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer

Summary: to determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

this study will help determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly, opposed to a weekly, dosing schedule of gemcitabine plus nab-pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Eligibility criteria:
inclusion criteria: 1. patients must have histologically-proven unresectable/metastatic pancreatic adenocarcinoma. 2. patient has one or more radiographically measurable tumor. 3. patients may have received prior adjuvant chemotherapy or radiation therapy (rt). 4. age ≥ 18 years. 5. patient must have read, understood, and provided written informed consent and hipaa authorization after full explanation of the nature of the study. 6. ecog performance status 0 - 2 and an expected survival of at least 3 months. 7. acceptable hematological parameters within 2 weeks of commencing study therapy as follows: * absolute neutrophil count (anc) ≥ 1.5 x 10\^9/l * platelet count ≥ 100 x 10\^9/l * hemoglobin (hgb) ≥ 9g/dl 8. patients with adequate organ function as measured by: a. cardiac: american heart association class i: patients with cardiac disease but without resulting limitation of physical activity. ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain. b. hepatic: bilirubin ≤ 2.0 mg/ and alt and ast ≤ 1.5x the upper limit of normal. c. renal: creatinine ≤ 1.5 mg/dl and no other chronic kidney disease. 9. women must meet one of the following criteria: * post-menopausal for at least one year * surgically incapable of child-bearing * utilizing a reliable form of contraception for the duration of study participation. women of child-bearing potential must have a negative serum β-hcg within 7 days of study drug administration. exclusion criteria: 1. previous use of nab-paclitaxel for treatment of pancreatic cancer either as monotherapy or combination in neo-adjuvant, adjuvant, or the metastatic setting. 2. previous use of any chemotherapy or radiation therapy for metastatic disease. 3. patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart). 4. other significant active or chronic infection. 5. history of active other malignancy excluding basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia. 6. pregnant or nursing females. 7. patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity. 8. major surgery, other than diagnostic surgery within 4 weeks of study entry. 9. patient requires a legal authorized representative for consenting.
telephone administered psychotherapy for the treatment of depression for veterans in rural areas

Conditions: Heart Failure; Beta-blocker Treatment

Summary: the purpose of this study is to examine the efficacy of telephone-administered cognitive-behavioral therapy (t-cbt) in treating major depression among veterans served by community-based outpatient clinics (cbocs) in the veteran�s integrated service network (visn) 21, which serves rural areas in northern california

more that 20% of patients in primary care have depressive disorders. while primary care is the principal venue for treatment for depression, fewer than 25% of depressed patients receive adequate treatment for their depression. these outcomes can be worse when there are barriers to treatment such as living in a rural area. several studies have found that given a choice, about two-thirds of depressed primary care patients prefer psychotherapy or counseling over antidepressant medication. this is a controlled, randomized trial in which subjects meeting criteria for major depressive disorder (mdd) from primary care settings in visn 21 including cbocs will be randomly assigned to one of two conditions: 1) a 16-session manualized telephone administered cognitive behavioral therapy (t-cbt) delivered over 24 weeks or 2) a treatment-as-usual (tau) condition. telephone-administered cognitive behavioral therapy (t-cbt) is an intervention aimed at improving coping skills and social functioning. it is divided into two phases: 1) an initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and 2) a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains. t-cbt, administered by doctoral level psychologists, will be compared to a treatment-as-usual (tau) condition that controls for the natural course of depression during the course of treatment.

Eligibility criteria:
inclusion criteria: patients must have chronic heart failure, systolic left ventricular dysfunction (ejection fraction less than or equal to 45%), not be receiving beta-blockers, and not have contraindications to beta-blockers. exclusion criteria:
a study of decitabine in combination with escalating doses of rapamycin in patients with relapsed or refractory acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to determine the safety and feasibility of the combination of decitabine given at a fixed dose with escalating doses of rapamycin in patients with relapsed or refractory acute myeloid leukemia.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * diagnosis of aml according to who criteria except acute promyelocytic leukemia and * refractory aml defined as a failure to achieve cr after 2 cycles of induction chemotherapy or persistence of \> 40% bone marrow blasts after one cycle of chemotherapy induction or * relapsed aml defined as any evidence of disease recurrence within 12 months of achieving first cr or * relapsed aml after stem cell transplantation 100 days must have elapsed between transplant and emergence of recurrent aml * ecog performance status \<3 (appendix 1) exclusion criteria: * abnormal renal function as evidenced by a calculated creatinine clearance ≤ 30ml/min (cockcroft-gault formula (appendix 2) * abnormal liver function: bilirubin \>2.0 mg/dl, transaminase more than 2.5x the upper limits of normal * active systemic infection * known chronic liver disease * known diagnosis of human immunodeficiency virus infection (hiv) * patients who are post-allogeneic transplantation should not have active gvhd greater than grade 1 of skin * pregnant or breast feeding female subjects
alternating icotinib and chemotherapy for advanced non-small cell lung cancer with egfr mutation

Conditions: Lung Adenocarcinoma

Summary: this is a prospective, open, single-center, phase ⅱ study to assess the efficacy and safety of alternating icotinib and chemotherapy for advanced non-small cell lung cancer with egfr mutation.


Eligibility criteria:
inclusion criteria: 1. histological or cytological confirmation of non-small cell lung cancer (nsclc) in phase ⅲb or phase ⅳ. 2. positive egfr mutation(19 exon or 21 exon)。 exclusion criteria: 1. previous usage of egfr-tki or antibody to egfr: gefitinib, erlotinib, herceptin, erbitux. 2. severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases. 3. allergic to icotinib 4. metastases of spinal cord, meninges or meningeal.

Keywords: icotinib chemotherapy egfr
evaluation of efficacy and safety of an anti-allergy drug with a contact lens in the treatment of allergic conjunctivitis

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis


Eligibility criteria:
inclusion criteria: * history of ocular allergies and a positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees withing the past 24 months * successful soft contact lens wearer who has frequently worn contact lenses for at least one month or more exclusion criteria: * active ocular infection * clinically significant blepharitis * follicular conjunctivitis * pterygium * narrow angle glaucoma * dry eye dyndrome * ocular surgery within past 6 months * pregnancy or lactation

Keywords: allergic conjunctivitis, ophthalmology, multicenter, controlled
identification of new candidate genes for hereditary predisposition to uveal melanoma

Conditions: Uveal Melanoma

Summary: only 20% of familial uveal melanomas are explained by a hereditary predisposition, implying the presence of as yet unknown hereditary predispositions. this hypothesis is reinforced by epidemiological studies revealing an excess risk of prostate cancer, thyroid cancer and leukemia in patients who have developed uveal melanoma, even though these cancers are not part of the tumor spectrum of known hereditary predispositions to uveal melanoma (bap1, mbd4). the identification of new candidate genes, once validated, would enable us to offer these families appropriate surveillance.


Eligibility criteria:
inclusion criteria: * patient with a personal history of uveal melanoma (newly diagnosed, under treatment or in follow-up) * enrolled in or benefiting from a social security scheme exclusion criteria: * causal pathogenic variation identified in bap1 or mbd4 * patient does not consent to constitutional genetic analysis for diagnostic purposes * patient not consenting to a constitutional genetic analysis for research purposes * pregnant and breast-feeding women * patients under guardianship or trusteeship

Keywords: uveal melanoma hereditary predisposition candidate genes identification
predictors of mortality and morbidity in the surgical management of primary tumors of the spine

Conditions: Spine Tumor

Summary: within defined groups of primary malignant and benign bone and soft tissue spine tumors, what variables (clinical, diagnostic, therapeutic, and/or demographic) are associated with overall survival?

primary tumors of the spine are exceedingly rare and therefore the literature has been limited to case series of limited size and significant heterogeneity. these tumors comprise 11% of all primary musculoskeletal tumors and 4.2% of all spine tumors. of all primary spine tumors only 6% are malignant, but it is the malignant tumors that present the greatest therapeutic challenges. through this multi-center retrospective cohort study performed at 13 spine oncology referral, data on at least 2.000 patients with specific primary benign and malignant spine tumors will be collected. this will provide power to determine the influence of many previously hypothesized variables on outcome. the purpose of this study is to determine clinical, imaging and treatment factors that influence patient survival, local recurrence rate, and peri-operative/post-operative morbidity. most surgical options carry significant morbidity and consume vast resources. in contrast, there is emerging evidence that incomplete or oncologically inappropriate resection increases local recurrence rate and decreases overall survival. these data will be used to refine existing study questions regarding patient outcomes and to develop new study questions that will be assessed in the future using prospectively collected data.

Eligibility criteria:
inclusion criteria: * were admitted to one of the participating spine centers with a diagnosis of primary tumor of the spine and were treated surgically. * at least one follow-up detectable in the medical charts exclusion criteria: * metastatic tumor of the spine * primary spinal cord tumor
a 24-week off-drug extension study in sarcopenic elderly who completed treatment in the 6-month core study

Conditions: Sarcopenia

Summary: this extension study was a 24-week off-drug follow-up of the core cbym338e2202 (nct ) study and the main objective was to determine the long-term durability of bimagrumab (bym338) effect after a 6-month treatment period.

two populations were defined as below: * population i: patients enrolled prior to the protocol amendment 1, who received bimagrumab 70 mg, 210 mg or 700 mg in the core study, were randomly assigned to two subgroups within each of three treatment arms to either receive bimagrumab at the same dose level or placebo. patients receiving placebo in the core study continued receiving placebo in the extension study. * population ii: patients enrolled after protocol amendment 1, who received bimagrumab 700 mg or placebo in the core study, did not receive study medication in the extension study and were followed-up per schedule defined in this protocol amendment.

Eligibility criteria:
inclusion criterion: - men and postmenopausal women aged 70 years or older that have participated in, and have completed the full study treatment period per protocol (24 weeks/eot visit) in the preceding core study (cbym338e2202) exclusion criterion: - any condition which should have led to treatment discontinuation per protocol in the core study (cbym338e2202)

Keywords: sarcopenia, muscle wasting, elderly, strength, physical function, lean body mass, gait speed
evaluation of the supported housing system for the inclusion of people suffering from mental disorders

Conditions: Mental Disorder

Summary: access to housing, in the current context of extreme tension in the rental housing market in paris and throughout the ile-de-france region, is proving to be extremely complex for people with mental health problems.national and international scientific studies have quantified the problem of homelessness and precarious or inappropriate housing among patients suffering from psychiatric disorders, and show the impact of housing problems on the consumption of psychiatric care.the délai's mission is to facilitate access to housing for people enrolled in a psychiatric care pathway, with teams from the psychiatric sectors

* written and oral information provided to the patient by the patient's referring psychiatrist (investigator of one of the five recruiting sites) during a regular consultation appointment. * initial assessment (v inclusion): reminder of the information concerning the research, collection of consent, collection of sociodemographic data, and standardized assessment scales (quality of life, clinical state, level of functioning) + standardized semi-structured interview for the diagnosis of psychiatric disorders + completion by the referring psychiatrist of the data corresponding to the patient's care pathway. * then follow-up visit at an annual rate (v1 ... vx), and dlai exit assessment (v exit) as soon as the patient stops benefiting from the dlai.

Eligibility criteria:
inclusion criteria: patient followed for a psychiatric disorder patient benefiting from a dlai exclusion criteria: patient not followed for psychiatric disorder patient who refused to participate in the research